Remember the “powerhouse of the cell” from science class? That’s right, that mitochondrial knowledge is coming back around. These cellular organelles are most known for their role in energy production. Mitochondrial dysfunction is emerging as a key feature of lipedema pathophysiology.
Big picture—lipedema fat cells have dysregulated mitochondria, but it isn’t until the hormone shift of menopause that we tend to see a big shift in inflammation and fibrosis.
Studies have shown that lipedema adipose tissue exhibits profound downregulation of mitochondrial functions, including impaired cellular respiration and oxidative phosphorylation pathways. This mitochondrial impairment is accompanied by disruption of the sirtuin pathway, which normally regulates mitochondrial function and cellular metabolism. It has been proposed that this may be a compensatory mechanism—an adaptive metabolic reprogramming.
Unlike traditional obesity, which is also associated with mitochondrial dysfunction, lipedema fat is associated with better glucose regulation and is considered metabolically “healthy,” at least until menopause. Lipedema tissue may be attempting to maintain energy homeostasis while managing the stress of adipose expansion. [1-2]
A Metabolic Shift in Menopause
The mitochondrial downregulation that may be compensatory during reproductive years likely becomes maladaptive after menopause and may be particularly detrimental in lipedema. Without estrogen’s protective effects on mitochondrial function, oxidative stress, and inflammation, the reduced oxidative capacity can no longer support healthy adipose expansion. [3-4] The tissue becomes hypoxic, fibrotic, and insulin-resistant—characteristics of metabolically unhealthy adipose tissue. [5]
In normal adipose tissue, estrogen deficiency due to menopause causes impaired mitochondrial fatty acid β-oxidation and favors lipogenesis (fat production) over fat oxidation. [6] Fundamentally this is changing the balance between lipid storage and mobilization. Postmenopausal women show a combination of reduced fat breakdown (lipolysis) and increased fat uptake—predisposing to continued fat accumulation after menopause. [7]
This metabolic shift toward lipid storage mirrors and likely exacerbates the pre-existing mitochondrial dysfunction in lipedema tissue.
From Anti-Inflammatory to Pro-Inflammatory State
The inflammatory transition occurs through multiple mechanisms.
Menopause shifts adipose tissue from an anti-inflammatory M2 macrophage phenotype toward a pro-inflammatory M1 response. [5] This directly opposes the M2 predominance that characterizes lipedema during reproductive years. [1][8]
Estrogen exerts powerful anti-inflammatory effects on adipose tissue that are lost at menopause. [4,9-10] Estrogen reduces adipose tissue inflammation by suppressing TNF-α and IL-6 production, improving insulin-mediated suppression of lipolysis, and reducing lipid deposition in liver and muscle. [10] The loss of these protective effects at menopause leads to increased adipose tissue inflammation, triggering a cascade of metabolic dysfunction. [9-10][11]
Intracrine Estrogen Excess Hypothesis
Paradoxically, while systemic estrogen levels decline at menopause, adipose tissue becomes a major source of local estrogen production through aromatase activity. [4] Aromatase is an enzyme that converts androgens (like testosterone) into estrogen. Postmenopausal women with obesity have higher circulating estrogen levels than lean postmenopausal women due to increased adipose tissue aromatization. [4] In lipedema, this may create a state of intracrine estrogen excess—high local estrogen production despite low systemic levels. [1]
This local estrogen excess, combined with altered estrogen receptor function (particularly ERα activation due to CAV1 dysfunction discussed more here), may perpetuate the pathologic adipose expansion while simultaneously losing the systemic metabolic benefits of estrogen. [1][3] The tissue continues to grow but loses its metabolic health characteristics.
Clinical Implications
The menopause transition may represent an important window for intervention in lipedema. The shift from compensatory to pathologic mitochondrial dysfunction, combined with loss of estrogen’s anti-inflammatory and metabolic protective effects, suggests that strategies to preserve metabolic health during this transition could help prevent disease progression.
Studies show that estrogen replacement partially reverses many of these changes, improving insulin sensitivity, reducing triglyceride deposition, and normalizing the adipose tissue metabolism toward a healthier profile. [3][6] This suggests that the menopause-related metabolic deterioration is at least partially reversible with hormonal intervention. However, whether hormone replacement therapy or other interventions targeting estrogen signaling can modify lipedema progression remains an important unanswered question. [2][12]
Sources
- Lipedema and Adipose Tissue: Current Understanding, Controversies, and Future Directions. Frontiers in Cell and Developmental Biology. 2025. Rabiee A.
- Impact of Hormones on Lipedema Development: A Systematic Literature Review. Archives of Gynecology and Obstetrics. 2026. Lüchinger JE, Pavicic E, Giachino CL, Stute P.
- The Effect of Ovariectomy and Estradiol Substitution on the Metabolic Parameters and Transcriptomic Profile of Adipose Tissue in a Prediabetic Model. Antioxidants. 2024. Marková I, Hüttl M, Miklánková D, et al.
- Health of Adipose Tissue: Oestrogen Matters. Nature Reviews. Endocrinology. 2025. Vieira-Potter VJ, Mishra G, Townsend KL.
- Changes in Abdominal Subcutaneous Adipose Tissue Phenotype Following Menopause Is Associated With Increased Visceral Fat Mass. Scientific Reports. 2021. Abildgaard J, Ploug T, Al-Saoudi E, et al.
- Ovariectomy Modifies Lipid Metabolism of Retroperitoneal White Fat in Rats: A Proteomic Approach. American Journal of Physiology. Endocrinology and Metabolism. 2020. Boldarine VT, Pedroso AP, Brandão-Teles C, et al.
- Differences in Adipose Tissue Metabolism Between Postmenopausal and Perimenopausal Women. The Journal of Clinical Endocrinology and Metabolism. 2002. Ferrara CM, Lynch NA, Nicklas BJ, Ryan AS, Berman DM.
- Lipedema Stage Affects Adipocyte Hypertrophy, Subcutaneous Adipose Tissue Inflammation and Interstitial Fibrosis. Frontiers in Immunology. 2023. Kruppa P, Gohlke S, Łapiński K, et al.
- Menopause-Related Estrogen Decrease and the Pathogenesis of HFpEF: JACC Review Topic of the Week. Journal of the American College of Cardiology. 2020. Sabbatini AR, Kararigas G.
- Anti-Inflammatory Effects of Oestrogen Mediate the Sexual Dimorphic Response to Lipid-Induced Insulin Resistance. The Journal of Physiology. 2019. Camporez JP, Lyu K, Goldberg EL, et al.
- Sex Hormones Regulate Metainflammation in Diet-Induced Obesity in Mice.The Journal of Biological Chemistry. 2021. Varghese M, Griffin C, Abrishami S, et al.
- Lipedema: Progress, Challenges, and the Road Ahead. Obesity Reviews : An Official Journal of the International Association for the Study of Obesity. 2025. Cifarelli V.
